Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis

Brain metastases of breast cancer seem to be increasingin incidence as systemic therapy improves. Metastatic disease in the brain is associated with high morbidity and mortality. We present the first gene expression analysis of laser-captured epithelial cells from resected human brain metastases of breast cancer compared with unlinked primary breast tumors. The tumors were matched for histology, tumor-node-metastasis stage, and hormone receptor status. Most differentially expressed genes were down-regulated in the brain metastases, which included, surprisingly, many genes associated with metastasis. Quantitative real-time PCR analysis confirmed statistically significant differences or strong trends in the expression of six genes: BMP1, PEDF, LAMγ3, SIAH, STHMN3, and TSPD2. Hexokinase 2 (HK2) was also of interest because of its increased expression in brain metastases. HK2 is important in glucose metabolism and apoptosis. In agreement with our microarray results, HK2 levels (both mRNA and protein) were elevated in a brain metastatic derivative (231-BR) of the human breast carcinoma cell line MDA-MB-231 relative to the parental cell line (231-P) in vitro. Knockdown of HK2 expression in 231-BR cells using short hairpin RNA reduced cell proliferation when cultures were maintained in glucose-limiting conditions. Finally, HK2 expression was analyzed in a cohort of 123 resected brain metastases of breast cancer. High HK2 expression was significantly associated with poor patient survival after craniotomy (P = 0.028). The data suggest that HK2 overexpression is associated with metastasis to the brain in breast cancer and it may be a therapeutic target. (Mol Cancer Res 2009;7(9):1438–45)

[1]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Hay,et al.  Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt , 2006, Oncogene.

[3]  Lori L. Holt,et al.  General Auditory Processes Contribute to Perceptual Accommodation of Coarticulation , 2000, Phonetica.

[4]  L. Carey,et al.  Central nervous system metastases in women after multimodality therapy for high risk breast cancer , 2004, Breast Cancer Research and Treatment.

[5]  S. Pinder,et al.  Brain metastases from breast cancer: identification of a high-risk group. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[7]  K. Togashi,et al.  Expression of Glucose Transporter-1, Hexokinase-II, Proliferating Cell Nuclear Antigen and Survival of Patients with Pancreatic Cancer , 2007, Cancer investigation.

[8]  M. Deshmukh,et al.  Glucose Metabolism Inhibits Apoptosis in Neurons and Cancer Cells by Redox Inactivation of Cytochrome c , 2008, Nature Cell Biology.

[9]  H. Lee,et al.  Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. , 2007, Anticancer research.

[10]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[11]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[12]  P. Andersen,et al.  Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy , 2005, Breast Cancer Research and Treatment.

[13]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[14]  J. Li,et al.  Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. , 2000, Cancer research.

[15]  S. Steinberg,et al.  Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.

[16]  E. Winer,et al.  Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.

[17]  D. Balinsky,et al.  Enzyme activities in normal, dysplastic, and cancerous human breast tissues. , 1984, Journal of the National Cancer Institute.

[18]  P. Pedersen.  Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment’s roles together with hexokinase-2 in the “Warburg effect” in cancer , 2008, Journal of Bioenergetics and Biomembranes.

[19]  F. André,et al.  Risk factors for brain relapse in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  V. Shoshan-Barmatz,et al.  Methyl jasmonate binds to and detaches mitochondria-bound hexokinase , 2008, Oncogene.

[21]  Y. Ohta,et al.  Suppression of Apoptosis by Cyclophilin D via Stabilization of Hexokinase II Mitochondrial Binding in Cancer Cells* , 2006, Journal of Biological Chemistry.

[22]  B. V. van Oirschot,et al.  Glycolytic enzyme activities in breast cancer metastases. , 1988, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[23]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[24]  Paul J. Williams,et al.  A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  S. Hilsenbeck,et al.  Primary breast cancer phenotypes associated with propensity for central nervous system metastases , 2006, Cancer.

[26]  L. Galluzzi,et al.  Disruption of the hexokinase–VDAC complex for tumor therapy , 2008, Oncogene.

[27]  R. Beitner,et al.  Lithium detaches hexokinase from mitochondria and inhibits proliferation of B16 melanoma cells. , 2003, Molecular genetics and metabolism.

[28]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Hoek,et al.  Regulation of hexokinase binding to VDAC , 2008, Journal of bioenergetics and biomembranes.

[30]  R. Beitner,et al.  Clotrimazole decreases glycolysis and the viability of lung carcinoma and colon adenocarcinoma cells. , 2002, European journal of pharmacology.

[31]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[32]  T. Higuchi,et al.  Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]‐2‐fluro‐2‐deoxy‐d‐glucose positron emission tomography , 2008, Cancer science.

[33]  T. A. Smith,et al.  Mammalian hexokinases and their abnormal expression in cancer. , 2000, British journal of biomedical science.

[34]  Y. Olsson,et al.  Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells , 1995, Journal of the Neurological Sciences.

[35]  J. Price,et al.  Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[36]  Qi Zhou,et al.  Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo , 2008, Cancer biology & therapy.

[37]  R. Weil,et al.  Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.

[38]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[39]  H. Hsu,et al.  Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. , 2008, Oncology reports.

[40]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[41]  I. Brink,et al.  Factors Influencing [F‐18] 2‐Fluoro‐2‐Deoxy‐d‐Glucose (F‐18 FDG) Uptake in Melanoma Cells: The Role of Proliferation Rate, Viability, Glucose Transporter Expression and Hexokinase Activity , 2005, The Journal of dermatology.